These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 24365641)

  • 41. Progress in biosimilar monoclonal antibody development: the infliximab biosimilar CT-P13 in the treatment of rheumatic diseases.
    Braun J; Kudrin A
    Immunotherapy; 2015; 7(2):73-87. PubMed ID: 25713985
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Biosimilars: An Opportunity to Update the Product Information of Biological Drugs Regarding their Immunogenicity.
    Borrega R; Cruz JP; Taylor P; Goncalves J
    BioDrugs; 2019 Dec; 33(6):693-695. PubMed ID: 31654334
    [No Abstract]   [Full Text] [Related]  

  • 43. ECCO position statement: the use of biosimilar medicines in the treatment of inflammatory bowel disease (IBD).
    Danese S; Gomollon F;
    J Crohns Colitis; 2013 Aug; 7(7):586-9. PubMed ID: 23623738
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The scientific and regulatory rationale for indication extrapolation: a case study based on the infliximab biosimilar CT-P13.
    Reinisch W; Louis E; Danese S
    Expert Rev Gastroenterol Hepatol; 2015; 9 Suppl 1():17-26. PubMed ID: 26395531
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Use of biosimilars in inflammatory bowel disease: Statements of the Italian Group for Inflammatory Bowel Disease.
    Annese V; Vecchi M;
    Dig Liver Dis; 2014 Nov; 46(11):963-8. PubMed ID: 25139379
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Biosimilar safety factors in clinical practice.
    Reinisch W; Smolen J
    Semin Arthritis Rheum; 2015 Jun; 44(6 Suppl):S9-15. PubMed ID: 26058551
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Biosimilar drugs, myths and reality.
    Hernández-García C
    Reumatol Clin; 2014; 10(6):351-2. PubMed ID: 25037069
    [No Abstract]   [Full Text] [Related]  

  • 48. Infection, malignancy, switching, biosimilars, antibody formation, drug survival and withdrawal, and dose reduction: what have we learned over the last year about tumor necrosis factor inhibitors in rheumatoid arthritis?
    Ianculescu I; Weisman MH
    Curr Opin Rheumatol; 2016 May; 28(3):303-9. PubMed ID: 26927443
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effective pharmaceutical regulation needs alignment with doctors.
    Ebbers HC; Pieters T; Leufkens HG; Schellekens H
    Drug Discov Today; 2012 Feb; 17(3-4):100-3. PubMed ID: 22001600
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Biosimilar versions of anti-TNF drugs could save NHS money, drug company claims.
    Hawkes N
    BMJ; 2015 Oct; 351():h5337. PubMed ID: 26442517
    [No Abstract]   [Full Text] [Related]  

  • 51. Biosimilars: in support of extrapolation of indications.
    Ebbers HC
    J Crohns Colitis; 2014 May; 8(5):431-5. PubMed ID: 24594005
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Biosimilar infliximab: an expert view.
    Genazzani A; Altomare G; Balato N; Cusano F; De Pità O; Loconsole F; Micali G; Piaserico S; Girolomoni G
    G Ital Dermatol Venereol; 2015 Aug; 150(4):449-59. PubMed ID: 25747260
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Infliximab (Remicade) for Crohn's disease.
    Med Lett Drugs Ther; 1999 Feb; 41(1047):19-20. PubMed ID: 10076592
    [No Abstract]   [Full Text] [Related]  

  • 54. Infliximab: new indication. Severe Crohn's disease in children: many unknowns.
    Prescrire Int; 2008 Aug; 17(96):145. PubMed ID: 19489184
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Biosimilars in inflammatory bowel diseases: an important moment for Brazilian gastroenterologists.
    Teixeira FV; Kotze PG; Damião AO; Miszputen SJ
    Arq Gastroenterol; 2015; 52(1):76-80. PubMed ID: 26017088
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Biosimilar safety considerations in clinical practice.
    Choy E; Jacobs IA
    Semin Oncol; 2014 Feb; 41 Suppl 1():S3-14. PubMed ID: 24560025
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Tumor necrosis factor inhibitors: clinical utility in autoimmune diseases.
    Willrich MA; Murray DL; Snyder MR
    Transl Res; 2015 Feb; 165(2):270-82. PubMed ID: 25305470
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A scientific update on biosimilar infliximab (CT-P13) in rheumatic diseases.
    Taylor P
    Expert Rev Clin Immunol; 2015; 11 Suppl 1():S1-4. PubMed ID: 26395831
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Shared experiences and best practices in the management of rheumatoid arthritis and Crohn's disease.
    Kavanaugh AF; Mayer LF; Cush JJ; Hanauer SB
    Am J Med; 2011 Apr; 124(4 Suppl):e1-18. PubMed ID: 21531240
    [No Abstract]   [Full Text] [Related]  

  • 60. Cimzia's setback paves way for other TNF inhibitors in Crohn's disease.
    Sheridan C
    Nat Biotechnol; 2007 May; 25(5):487-8. PubMed ID: 17483820
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.